Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
Condition(s):Acute Myeloid LeukemiaLast Updated:November 18, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Acute Myeloid LeukemiaLast Updated:November 18, 2023Active, not recruiting
Condition(s):Acute Myelogenous LeukemiaLast Updated:December 21, 2010Terminated
Condition(s):Acute Myeloid Leukemia (AML)Last Updated:September 14, 2021Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:February 21, 2024Completed
Condition(s):Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, Relapsed, AdultLast Updated:March 29, 2023Recruiting
Condition(s):Acute Myeloid LeukemiaLast Updated:July 26, 2016Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:February 21, 2023Completed
Condition(s):Acute Myeloid LeukemiaLast Updated:March 31, 2020Withdrawn
Condition(s):Leukemia, Myeloid, AcuteLast Updated:September 7, 2015Completed
Condition(s):Leukemia, Myeloid, AcuteLast Updated:January 3, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.